X4 Pharmaceuticals, Inc (XFOR) SEC Filings & Earnings Calls

Debt service obligations and potential dilution from warrants remain; additional tranches subject to conditions.

“The warrants to purchase shares of the Company’s common stock previously issued to Hercules and its affiliates remain outstanding in accordance with their terms. An additional $70 million may be made available to X4 at the Company’s request, subject to approval by K2HV and other conditions.”

Clinical trial and regulatory risks remain; no approved product yet.

“Phase 3 trial still ongoing; FDA approval not guaranteed.”

Going concern risk

“Although the Company has an approved drug product, licensing and sales of the Company's drug product over the next 12 months will not be sufficient to fund the Company's operating expenses.” · word for word

Dilution risk

“Weighted average shares outstanding increased from 7,412,990 in Q2 2025 to 126,344,020 in Q2 2026, reflecting significant equity issuance.”

Debt maturity risk

“As of June 30, 2026, future principal and accrued end-of-term payments of $77.0 million under the Hercules Loan Agreement are due on July 1, 2027.” · word for word

Going concern risk due to ongoing losses and negative cash flows

“Since inception, the Company has incurred significant operating losses and negative cash flows from operations, and the Company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future.” · word for word

Dependence on single approved product XOLREMDI

“XOLREMDI, our one product approved for commercial sale, upon which we depend almost entirely to produce revenue, faces an unknown market size and growth potential, and we have not generated significant revenue from product sales to date.” · word for word

Substantial debt obligation due July 2027

“As of March 31, 2026, future principal and accrued end-of-term payments of $76.9 million under the Hercules Loan Agreement are due on July 1, 2027.”

Restructuring execution risk

“In 2025, the Company implemented two strategic restructuring actions designed to sharpen operational focus and align resources with the Company's long‑term strategy to successfully complete the 4WARD trial.” · word for word

Going concern risk

“Until we achieve profitability, our operations will require substantial additional funding. Our history of recurring losses and anticipated future expenditures could raise substantial doubts about our ability to continue as a going concern.” · word for word

Single product dependency

“We depend almost entirely on the success of our future product candidate, mavorixafor. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor for disorders other than WHIM, including CN, or any other product candidate.” · word for word

Clinical trial risk

“The 4WARD trial is a global, randomized, double-blinded, placebo-controlled trial assessing the safety and efficacy of once-daily oral mavorixafor... We expect to complete enrollment in the third quarter of 2026 and report top-line data results in the second half of 2027, with the goal of receiving FDA approval in 2028.”

Dilution risk

“Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates.” · word for word

Regulatory approval risk

“We may not be able to obtain regulatory approval for, or successfully commercialize, mavorixafor for disorders other than WHIM, including CN, or any other product candidate.”

Clinical trial execution risk for 4WARD Phase 3 trial; enrollment completion expected Q3 2026, with potential delays.

“Enrollment now expected to be completed in third quarter of 2026.” · word for word

Dependence on single product (mavorixafor) for future revenue; WHIM commercialization deprioritized.

“A deprioritization of the commercialization of mavorixafor (XOLREMDI) for patients with WHIM syndrome.” · word for word

Going concern / capital need

“Until we reach profitability, we will need to raise additional capital, which cannot be assured, to fund our operations and meet our financial obligations beyond this period.” · word for word

Commercialization risk

“XOLREMDI, our one product approved for commercial sale, upon which we depend almost entirely on to produce revenue faces an unknown market size and growth potential and we have not generated significant revenue from product sales to date, and we may never achieve profitability.” · word for word

Clinical trial risk

“The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll up to 176 patients, with full enrollment expected in Q3 2026.” · word for word